Quarterly ResultAug 6, 2026, 07:32 AM
Roivant Q1 Net Loss Attributable $(189.8)M; EPS $(0.26)
AI Summary
Roivant Sciences Ltd. reported a net loss attributable to the company of $(189.8) million, or $(0.26) per share, for the three months ended June 30, 2026, showing an improvement in EPS compared to the prior year. Revenue decreased to $1.4 million, while research and development expenses significantly increased to $202.0 million. The company maintained a strong liquidity position with $3.8 billion in cash, cash equivalents, and marketable securities.
Key Highlights
- Net loss attributable to Roivant Sciences Ltd. was $(189.8) million for the quarter.
- Diluted EPS was $(0.26), an improvement from $(0.33) in the prior year period.
- Revenue for the three months ended June 30, 2026, decreased to $1.4 million.
- Research and development expenses increased to $202.0 million, up from $152.9 million YoY.
- Cash, cash equivalents, and marketable securities totaled $3.8 billion as of June 30, 2026.
- Net cash used in operating activities increased to $(270.5) million from $(204.4) million YoY.
- Litigation settlement receivable stood at $771.6 million as of June 30, 2026.
Price Impact
More from ROIV